7 results for: GLP-1

Mounjaro

Indications

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Document title: Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11044191/pdf/cureus-0016-00000056939.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials Document link: https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15725 Document source: Diabetes Obesity and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians Document link: https://www.acpjournals.org/doi/full/10.7326/M23-1490?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org Document source: Annals of Internal Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11153294/pdf/125_2024_Article_6144.pdf Document source: Diabetologia Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951192/pdf/13300_2024_Article_1540.pdf Document source: Diabetes Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Document link: https://journals.sagepub.com/doi/10.1177/23969873241234238?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Document source: European Stroke Journal Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10823535/?report=printable Document source: BMJ Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis Document link: https://pdf.sciencedirectassets.com/272488/1-s2.0-S1043661823X00139/1-s2.0-S1043661823003870/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjECcaCXVzLWVhc3QtMSJIMEYCIQD%2FIlRiL0lhFZ7LvPoGUPIqh1R8fiveGz8t2oBmt1HD6wIhAIzf%2B0MqnvZFXimSydpzD7bHD4zeyRqry14jZt%2Fxh9mvKrIFCGAQBRoMMDU5MDAzNTQ2ODY1IgxqAy%2F9q3JZDDufGVUqjwU56ydVIcuPzf%2F02yjApnrmX6g4mKkbnH0JgENFDt3w%2FT3%2BtGM9C71TvCRc5Duaex1lXkSI%2BdilkbNurcu4n0aY497c%2Fw3wosvoSU26f0vLdpR3KJW9Xk1WZwwP%2B%2B7CoXCpZw6KmmClf5bNF6aRNnceV8rU9yrsIC7zKlExCAWcN2mopQxR9O%2Bvwc7UcIU11ziyNGMCDj1k9pSzl9Ds32nkVA2dYGCJ1RDPY3lCaHHS7jB4%2FbSMHfV71VMO7hO6R%2Fw8n6SMj%2BBAwWjXbT9DItk2TEV8qxOQE7wi5lCa8IKjXW9a%2Fj703Vc8A6JTArsPgvX8mKevDcCcUzbBT%2BvNjMwXd5sZHERGX2l4KENIh4pIBfv79LCbKHBden84XMSeL26laFved0%2B1n9R34B9xywzZdh5RHOeKqu5pPQiBqtnYC94VM56dg7%2BQeaaKXqRqE0c3WJbiZJhCEL7NRITkUnB%2B%2B4pYa%2Bgje58Qv%2Fs6pc37WQfTylZ51Xcze9c%2FIGqYtZQRghurZAmFjdzCnOyCda5jk9YMcSkSJ%2BsfrU%2FUag5E6NME1GQ0hfcbswhuotpkENBQ4n1eM3qgC67OzhmxtduyhTSFrjQde2eYFgmvP38qn8YrIZXty8KK0w2RD9YlvefGHEIlRnnAwukplkdYaA2gTvZqKxUSlFRYEvhWv5GLdJziMSZcgmKY82ffJwykyVaT6CXKkC0tRiqgXXUDwfvvmuqmkWBoaYBL%2FQC5XZuTCPkc1VCcH7Pv%2BaF08ip%2BOCnO11NgMp8DfuIsFTZGoYo3vsf9CVzs%2Bp6tsQLV9%2FLY%2BGtcv3MfUvVBTMD79rvma9vwQi2Rq597NBcUhX8ckeTheIQJY37ulC%2BDb0d%2BQSPcMMP3sLcGOrABTPs%2FOvq0xwJ%2BlnxoJSFLjGyF2wRHKu78sip4Qgo6O5NH4y%2F1M3bkz9xLnAFyDhFSHTbTdRcrZNLkNe%2FfErjoQpPSaPESPenI3RvZLHLoTdTHv6F3prdqJdmODd7MKQEh7Ib%2BjjNMHuc%2Fk7Bm2pxvEAlblYgUUwqX0bWDpzx5ZJVYbbWn%2FTsPTH5TY6sCEreHTjy%2BGYaMMAdmow7UQqt2V1h9D%2BfIrM7uhLIQsS7ME20%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20240919T160200Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY6HGHBOXT%2F20240919%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=5ecfc53e3c14b0f198153bbca9b85adc891cccfccb21b37c2d3d915adff64a83&hash=73922275f61b3c0e53ba65a9239a5052ed6337aa5287ab2c1c60dcd5ca1f241b&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1043661823003870&tid=spdf-ffa97ab7-1a7f-4c9c-838a-a3d8abf0feed&sid=e2128b995a72814fb57a56e5a981b6795429gxrqa&type=client&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t&ua=0d055a03520502065c&rr=8c5acc315b8ea31e&cc=ca Document source: Pharmacological Research Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus Document link: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15312 Document source: Diabetes Obesity and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Mounjaro (tirzepatide) Prescribing Information. Document link: https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi Document source: Lilly USA LLC, Indianapolis, IN Document type: Product Monograph / Prescribing Information Document year: 2023

Document title: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613702/pdf/fendo-14-1214334.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614464/pdf/cureus-0015-00000046091.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615484/pdf/medi-102-e35488.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614386/pdf/13098_2023_Article_1198.pdf Document source: Diabetology & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500557/pdf/main.pdf Document source: EClinicalMedicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493284/pdf/fendo-14-1244432.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis Document link: https://www.europeanreview.org/article/33290 Document source: European Review for Medical and Pharmacological Sciences Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253587/pdf/ijms-24-09760.pdf Document source: International Journal of Molecular Sciences Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077111/?report=printable Document source: BMJ Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide Document link: https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.14988 Document source: Diabetes Obesity and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472131/pdf/fcvm-09-990182.pdf Document source: Frontiers in Cardiovascular Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112245/pdf/125_2022_Article_5715.pdf Document source: Diabetologia Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938269/pdf/41591_2022_Article_1707.pdf Document source: Nature Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494570/pdf/fendo-13-920541.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials Document link: https://pdf.sciencedirectassets.com/273595/1-s2.0-S1871402122X00118/1-s2.0-S1871402122002545/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjECcaCXVzLWVhc3QtMSJIMEYCIQD%2FIlRiL0lhFZ7LvPoGUPIqh1R8fiveGz8t2oBmt1HD6wIhAIzf%2B0MqnvZFXimSydpzD7bHD4zeyRqry14jZt%2Fxh9mvKrIFCGAQBRoMMDU5MDAzNTQ2ODY1IgxqAy%2F9q3JZDDufGVUqjwU56ydVIcuPzf%2F02yjApnrmX6g4mKkbnH0JgENFDt3w%2FT3%2BtGM9C71TvCRc5Duaex1lXkSI%2BdilkbNurcu4n0aY497c%2Fw3wosvoSU26f0vLdpR3KJW9Xk1WZwwP%2B%2B7CoXCpZw6KmmClf5bNF6aRNnceV8rU9yrsIC7zKlExCAWcN2mopQxR9O%2Bvwc7UcIU11ziyNGMCDj1k9pSzl9Ds32nkVA2dYGCJ1RDPY3lCaHHS7jB4%2FbSMHfV71VMO7hO6R%2Fw8n6SMj%2BBAwWjXbT9DItk2TEV8qxOQE7wi5lCa8IKjXW9a%2Fj703Vc8A6JTArsPgvX8mKevDcCcUzbBT%2BvNjMwXd5sZHERGX2l4KENIh4pIBfv79LCbKHBden84XMSeL26laFved0%2B1n9R34B9xywzZdh5RHOeKqu5pPQiBqtnYC94VM56dg7%2BQeaaKXqRqE0c3WJbiZJhCEL7NRITkUnB%2B%2B4pYa%2Bgje58Qv%2Fs6pc37WQfTylZ51Xcze9c%2FIGqYtZQRghurZAmFjdzCnOyCda5jk9YMcSkSJ%2BsfrU%2FUag5E6NME1GQ0hfcbswhuotpkENBQ4n1eM3qgC67OzhmxtduyhTSFrjQde2eYFgmvP38qn8YrIZXty8KK0w2RD9YlvefGHEIlRnnAwukplkdYaA2gTvZqKxUSlFRYEvhWv5GLdJziMSZcgmKY82ffJwykyVaT6CXKkC0tRiqgXXUDwfvvmuqmkWBoaYBL%2FQC5XZuTCPkc1VCcH7Pv%2BaF08ip%2BOCnO11NgMp8DfuIsFTZGoYo3vsf9CVzs%2Bp6tsQLV9%2FLY%2BGtcv3MfUvVBTMD79rvma9vwQi2Rq597NBcUhX8ckeTheIQJY37ulC%2BDb0d%2BQSPcMMP3sLcGOrABTPs%2FOvq0xwJ%2BlnxoJSFLjGyF2wRHKu78sip4Qgo6O5NH4y%2F1M3bkz9xLnAFyDhFSHTbTdRcrZNLkNe%2FfErjoQpPSaPESPenI3RvZLHLoTdTHv6F3prdqJdmODd7MKQEh7Ib%2BjjNMHuc%2Fk7Bm2pxvEAlblYgUUwqX0bWDpzx5ZJVYbbWn%2FTsPTH5TY6sCEreHTjy%2BGYaMMAdmow7UQqt2V1h9D%2BfIrM7uhLIQsS7ME20%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20240919T161507Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY6HGHBOXT%2F20240919%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=90510360bda01764c76808333c75f3a4a9976473b550914bf5ab20de3d64ce2e&hash=a6f7f584a97bfe58610274eefd3477ebd9ddf39ea1b621e791fb0dcad4614fbd&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1871402122002545&tid=spdf-27f7719c-97a7-4ab4-988c-ad6db1b957c3&sid=e2128b995a72814fb57a56e5a981b6795429gxrqa&type=client&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t&ua=0d055a035205050359&rr=8c5adf646ceba2e8&cc=ca Document source: Diabetes & Metabolic Syndrome: Clinical Research & Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613929/pdf/fphar-13-998816.pdf Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774036/pdf/fphar-13-1016639.pdf Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537322/pdf/pharmaceuticals-14-00991.pdf Document source: Pharmaceuticals Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Adlyxin

Indications

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Document title: Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513082/pdf/fpubh-11-1201818.pdf Document source: Frontiers in Public Health Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis Document link: https://www.canadianjournalofdiabetes.com/action/showPdf?pii=S1499-2671%2823%2900057-6 Document source: Canadian Journal of Diabetes Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Document link: https://academic.oup.com/jcem/article/108/7/1806/7044761?login=false Document source: The Journal of Clinical Endocrinology and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Adlyxin (lixisenatide) Prescribing Information. Document link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf Document source: Sanofi-Aventis U.S. LLC., Bridgewater, NJ Document type: Product Monograph / Prescribing Information Document year: 2023

Document title: 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555541/pdf/dmj-2023-0282.pdf Document source: Diabetes & Metabolism Journal Document type: Clinical Practice Guidelines Document year: 2023

Document title: Recent updates to clinical practice guidelines for diabetes mellitus. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901964/pdf/enm-2022-105.pdf Document source: Endocrinology and Metabolism Document type: Clinical Practice Guidelines Document year: 2022

Document title: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008140/pdf/dci220034.pdf Document source: Diabetes Care Document type: Clinical Practice Guidelines Document year: 2022

Document title: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097124/pdf/12902_2022_Article_1036.pdf Document source: BMC Endocrine Disorders Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials Document link: https://www.primary-care-diabetes.com/article/S1751-9918(20)30253-9/abstract Document source: Primary Care Diabetes Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633575/pdf/main.pdf Document source: EClinicalMedicine Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553257/pdf/fendo-12-735824.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442438/pdf/12933_2021_Article_1366.pdf Document source: Cardiovascular Diabetology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: 2021 Clinical practice guidelines for diabetes mellitus in Korea. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369224/pdf/dmj-2021-0156.pdf Document source: Diabetes and Metabolism Journal Document type: Clinical Practice Guidelines Document year: 2021

Document title: Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947045/pdf/13300_2021_Article_1012.pdf Document source: Diabetes Therapy Document type: Clinical Practice Guidelines Document year: 2021

Document title: Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099977/pdf/13300_2021_Article_1034.pdf Document source: Diabetes Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322563/pdf/medi-100-e26431.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290816/pdf/DOM-23-2660.pdf Document source: Diabetes, Obesity & Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404431/pdf/bmjdrc-2021-002290.pdf Document source: BMJ Open Diabetes Research & Care Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials Document link: https://www.nmcd-journal.com/article/S0939-4753(20)30095-8/abstract Document source: Nutrition, Metabolism, and Cardiovascular Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies Document link: https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13553 Document source: International Journal of Clinical Practice Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310317/pdf/12933_2020_Article_1070.pdf Document source: Cardiovascular Diabetology Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials Document link: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.13847 Document source: Diabetes, Obesity & Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2019

Ozempic

Indications

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Document title: Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10823535/?report=printable Document source: BMJ (Clinical Research Ed.) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis Document link: https://www.endocrinepractice.org/article/S1530-891X(23)00758-9/abstract Document source: Endocrine Practice Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis Document link: https://pdf.sciencedirectassets.com/272488/1-s2.0-S1043661823X00139/1-s2.0-S1043661823003870/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEDYaCXVzLWVhc3QtMSJHMEUCIQD85uDMzG9F3NJq4ZVBoEExUkVI%2Fe64lgZJQsuxpTu5aAIgewFCrwx%2F2NJhG%2F3L0CpAe9OxgCmdmPAVMP3%2BnR5G06AqvAUIj%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAFGgwwNTkwMDM1NDY4NjUiDBTNZqKgnQ5QSJ14SiqQBU7xuiBBqRtb%2BQ0BFxxSqs07NEKYNUnYKsoPtLX0DLiKMlPIhP%2BsGyzald6QbUiNLPyCBPOkEKAtB%2BEp61N0fC6s5SCQ5hoVc118wXS5mGhhUEpl1hnrUQlIcQptTTtOTDKcjWx2GGiGQ%2BeGCY4Ll8VmITl%2BtCOiF8mHjQNmNHF7lK%2Bx3LLl7FKwab7oGOibZyDLxXzLLAVd037f5g1GPNl0Q4g8dgtpCs9bNugzhiasuzM5VLgiGBb8nbLBq11fMXOY2Je%2BlXgm%2BTYHZ1pIjPusUCSIo1AiPzIHkSFE%2FbgwKkMFQSvT94IK8RANt9wyJRQtcKm55OfEn1p86%2Fk7Dlvdutvp0Imazc8Dtd8%2BWBdPBG8DD8L1cCvU97uICI4TBh%2BgmLxvEGzzdaslj410JwwVWlILapRQQ44fIeJrEqMHHHEOEwRP3jzDUYLQwBLGrwEgU%2BSYSm6Zw0zgGPsPkaeY5R8a%2F7fKVUozGfMQgeZBl6wfDj7LPavtFx3Qdz3tsCB0UOnn%2Fi%2Fu2DOfaLQXaFtn0fbp5CxLSD2q4a%2BhsUq1jEqUFEylSsJAVxw%2F2X7v%2BhpHi42fJSE8vZCLiY85gwF1s%2FXGvh%2Bo7KsWcWMZ296TkU%2BtDMHszEe1RxDPHyRjImV5rIvwIUm0ZX48apb8P4tSWjU%2BAbkfHKqK3SkzX9I3TtWgFWDjErP1XbB9FWVSOhiL1U7NY61OVmLZKrOkM6D6E1by9lHkIxNI3biL%2FBkwBNLyksX%2BEWxGIPsVQTO7QchG5%2FClbVJJpuiSYc%2FaKzxiEIKU4%2BhMIaH9TM1PzOxpecJOtCMBclMauwls83dnmor9PFeEXV%2FWsTsmZgQFRfwZRPLLLqA5PXZDsD2hmI6QMPrZpLgGOrEBaPBlSZd2Qvkcvc5%2FuZWzJ52ueIfBya%2FjZgB7Wehvr9G6l%2Fjg8ZwOOPmvFNKkb%2FpmqOwJI1gl2XOlDixV%2Bgf4DIpZy5QjKeZwWbu9bJn0AmrKnJ21RM923SeQPwklvwM%2B29juECmXPRi0G9f%2Ba0dDu5NxdusNujS4waRJYKLkdlcCCB5UBXU1hOEWKjZVBYdCqrNf3xyTxnHu0zdcXLq%2B%2FOKh72Mui5XuzIdPzQC%2F3Bhg&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20241011T144511Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYWPIT6S5V%2F20241011%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=934e1105ee5aea36ea1fba6ce0a09c099a432169be98584af03570b2074ec906&hash=06e1db4e37485bbb192b7193bc12e7fa82bf18a258674c6c060cdda2cda7d82a&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1043661823003870&tid=spdf-6c8a05fd-c302-49c4-a5e8-3e96a62039f4&sid=c562ac0f1b9ec4483e7a73c6f248d9becd08gxrqa&type=client&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t&ua=05075b04570402530607&rr=8d0fa1eabf48ac0f&cc=ca Document source: Pharmacological Research Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10902041/pdf/12020_2023_Article_3636.pdf Document source: Endocrine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/obr.13717 Document source: Obesity Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923257/pdf/cr-15-001.pdf Document source: Cardiology Research Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10972401/pdf/medicina-60-00357.pdf Document source: Medicina (Kaunas, Lithuania) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050669/pdf/ijms-25-04346.pdf Document source: International Journal of Molecular Sciences Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Document link: https://www.ajconline.org/action/showPdf?pii=S0002-9149%2824%2900319-9 Document source: The American Journal of Cardiology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11084700/pdf/ijms-25-04972.pdf Document source: International Journal of Molecular Sciences Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11124640/pdf/medi-103-e38236.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/obr.13792 Document source: Obesity Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Clinical Pharmacokinetics of Semaglutide: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215664/pdf/dddt-18-2555.pdf Document source: Drug Design, Development and Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270812/pdf/fcvm-11-1379189.pdf Document source: Frontiers in Cardiovascular Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.14292 Document source: European Journal of Clinical Investigation Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303570/pdf/cureus-0016-00000064038.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376316/pdf/cureus-0016-00000066280.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326657/pdf/cureus-0016-00000064668.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression Document link: https://link.springer.com/article/10.1007/s40618-024-02459-3 Document source: Journal of Endocrinological Investigation Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437580/pdf/10.1177_17562864241281903.pdf Document source: Therapeutic Advances in Neurological Disorders Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11422096/pdf/fcvm-11-1453297.pdf Document source: Frontiers in Cardiovascular Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials Document link: https://www.metabolismjournal.com/article/S0026-0495(24)00266-X/abstract Document source: Metabolism: Clinical and Experimental Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384358/pdf/ajtr0016-3545.pdf Document source: American Journal of Translational Research Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials Document link: https://pdf.sciencedirectassets.com/782868/1-s2.0-S0002916522X00105/1-s2.0-S0002916523468463/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEDYaCXVzLWVhc3QtMSJIMEYCIQDGVxVnmUmsI8zB2pSwJlue8l3aDn1xX%2FZSH5VT4u9NrAIhAN%2FfAHBmbwmtwcVH5JagxsiHxgvizOB6rvjlvuQMG73yKrwFCI%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQBRoMMDU5MDAzNTQ2ODY1Igxi4evI2FHO6rUpKv4qkAWCMOZZeqtEA3oqWlvo%2B5IPoco%2Bu3gh6xJjMemzKSYoOCERrS9MOuImGqntfXcAMKUUs56onM1OjhW1235cGU%2BphwK32S4zhUKNN6ZN4B3mXR8B5kNPgkFUKXUBx3%2BmZwmA1G153y4zxfRgF4lkGokkdWMd1m7s9RBZPbTTX8n0txeNpwafshUtt475o0T5p3TF7MJyYfciy2w5jAth5oKWGf0CgLviKkIRp02HB7u1J%2FsEPU%2BVF5PiXDIyOa5XqTh11fRPmHtH%2FfVAfN7l%2FRIfW53iCXXmanzQT8BB7k9o%2F7yNtUuefhM%2FKNcKgwN3K76AnTZX%2FXsOJCfyGFrAuTkPTrXygpxE97Y4kaFXyODqB7OukbEI0gejUwzl%2BffHqxNWrI2fdCUsyuP0hE17QS0Vl7Dclod7PVDOOmQB%2Bj0fUgQsMwGU1tOArU0M%2Fo6yvJBtwWXgKutmN7aWBvSlqoopMqI7XmvecHp23JAIJbm0vfd9wHVgUdnCIzuOH6eIAliVpaZmfN69s89MEmsmdqKFmFd42A0WTaWtSnRJamHfCgg%2FhFvf5RwJpcXNOTqam5qitNu6B4soTwSIb%2BbZJekZTJz%2Bi0dQdHdTn9D6gAoa0rsshwkmipStLNIMgX2T8qywBqxGPwNEdCPa99IobVTyZqHCQW39UO96spUqJZUFhWuNHYSJDKURL8wyalMJXiBZ1wycgl%2F%2BBMoB9k9C7Ru1Ls%2FRzygwFPfl3xQUuvwkHt75IhMGG0lwl6vKtAAMrv4BtUm2QvzJrO55b4brhZarORLEndzNAX6ZbAOwvhDQRe0Fu3aCKXukFsGc3G03cGEJC2a5b6YP6SZxAT0KK5AZGqRgZdQ1VVouwA0U3QPgIDC4zaS4BjqwAc7BpOkRkLeenwqHSQeDo45TJXJJtZXq5Z8qlHr15Gz3iWE94gcoyU1zcWU0s2tAW8cYBTittL3X04PkjslzxnGCuwHJhFTIQZFlhEHgV9%2Bq1DOzplI7eWsm54%2B%2FcxQ6xHi7eM1IHpbs%2F14EzOMSfqD%2Fkv1PSqnPjEo4CMN%2FpzKr5VoxBlilxP5HsGN37PWJ1QvdAp6XlFh2NkuGOSjEQY4Qqc4zByFeoYmR1BrJS2Up&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20241011T144704Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYWPOPIKFZ%2F20241011%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=ae4eee524ff9cd8094fdd27ced2cdee00ff619234a8e7e6cdacb86f08b40ab4d&hash=7467e050d33fb0430a0b6c3e3a4a34ab6e2da2b14799cc077245ea9fc5de16c5&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S0002916523468463&tid=spdf-4d455e2f-067f-4df0-af49-cf349baab35b&sid=c562ac0f1b9ec4483e7a73c6f248d9becd08gxrqa&type=client&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t&ua=05075b04570402560202&rr=8d0fa4ad0a7bac0f&cc=ca Document source: The American Journal of Clinical Nutrition Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Ozempic (semaglutide) Prescribing Information. Document link: https://www.novo-pi.com/ozempic.pdf Document source: Novo Nordisk Inc., Plainsboro, NJ Document type: Product Monograph / Prescribing Information Document year: 2023

Document title: The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917722/pdf/jcm-12-00772.pdf Document source: Journal of Clinical Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008474/pdf/bmjopen-2022-061807.pdf Document source: BMJ Open Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.16126 Document source: Internal Medicine Journal Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277636/pdf/fendo-14-1170881.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570198/pdf/40273_2023_Article_1268.pdf Document source: PharmacoEconomics Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328610/pdf/medi-102-e34122.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375936/pdf/IANN_55_2239830.pdf Document source: Annals of Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612199/pdf/13098_2023_Article_1195.pdf Document source: Diabetology & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials Document link: https://link.springer.com/article/10.1007/s40261-021-01110-w Document source: Clinical Drug Investigation Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016460/?report=printable Document source: The Journal of Clinical Endocrinology and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6 Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052629/pdf/12933_2022_Article_1489.pdf Document source: Cardiovascular Diabetology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes Document link: https://www.sciencedirect.com/science/article/abs/pii/S1871402122001254?via%3Dihub Document source: Diabetes & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis Document link: https://pdf.sciencedirectassets.com/273595/1-s2.0-S1871402122X00064/1-s2.0-S1871402122001539/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEDcaCXVzLWVhc3QtMSJHMEUCIHkjV8OBUhrdmIDmxI7LlyHyLlJLQOLx7VUl%2Ff3O6ZmsAiEA0IEtUYj2Fay%2F1cfslosTBQb6%2F5wU5YB6CiH9MGGgvuAqvAUIj%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAFGgwwNTkwMDM1NDY4NjUiDEPMTA%2BlcS9FQmoOWSqQBY4fsbl2LKTBfJIAVvssZJSKwPPNEc2B63xvhTzMG5FrvKhj2CGW4sBmEHqRrfG7%2FcXBNQYmfwRNBX8DOaKq3%2B544ABNzBqNcES%2FwjbJ6mYjIohTeP7DjGq0%2BI8asA7oAtL9gOQ75FV5ckUlf%2BriYIjQ1UFilhrK0njkq0znXQU%2FLw8tU2kFvxkxHi9Duj%2FDQ8%2B9GXJVVTLSopX1rerViX9DHr0HLiCWdR7COQ0k35hgauo%2FaxuEK4Ur0mM5vR7FDWvcYuML6S4VLHW%2BzsLGt5ad6SRT8KMbB78SkxutH11rnxlcZZgnJy%2BFrggMr2VNbwnJYhh4myH9RCbE2L712FXjm%2FV%2FIZNIJJiOpUd5xhk%2BtKbmtR8uP0mAYy%2FqsSiY%2FgmTGQ%2F5nb0%2F%2BvcHIeMVKQd2WmNI6knnxTl3lvnukrHOvEEYiB5Y5Om%2BVxhEEHGXjL2tJ6y3GiprE9qJ%2BUXrEPGwBSD%2F%2FNMPsslP1Dw7W3Ac2f81AKeNq2p55itKHJniXLv1my3fG341S8OpABTCWDUU7y3FhUKrttU9hdsi5xbbcG6%2FG5G71WLs156pu1AKY8GnS0mf0Pk7FC8rSTA1u2yyBbJhedfG0BqWgrd6vQqfp5km8U1Weu%2FU75iTeuez%2B0Rl0BcuI%2BKu5SStukM%2BAvUh9CuoQeazfntFenXtENivU2LXFJeHAOokDgZAiuwa%2BmdKz2vPM3876KzvLCLWLMPKHNQdq9eXXFdKTgUR10df8q5mSmi%2FRqA%2BfEzD7vbKzXgH8fOkmgmdWYYXpfDRwjpY3wl8rDxswWq%2FWdTwrp053dGA%2BVUbKCEnpa%2BBkb5agHtmvJwX4P6Qw1fbUfEAy9h3jjKpGjDMEkqNucd1TwcnMJXnpLgGOrEBzcJ30ymRWmT4rq5gtd7qb10eFuL7pgerKS3UGkGU5htEQeORyql2S%2Ffb1YtdczLODrR3SgcYhRpGv2HpK1rindblNWehVvO4PFjkDCBv9xkdZV%2B3m1Ngony0I1DtW4MwA62Zk5DMWgV01CBU41Js4c0V2q9ebacTM6i215JxsQZczGmvjfimy%2FM4ZFI6XKnVziscV1nJThOwPIDYkE291ykewJuPxyHSXyp7IDE%2BXwMJ&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20241011T145302Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY3XQIJHTC%2F20241011%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=fa4d012a73ebdb11a97ee69f1d8d90f2dbb0d6f2c2b33e88fda05d48b6835107&hash=4de737a5861c283244b8d8628a01a3fd3f8fa29ac1c64a3dc45ef9b5b65f4b39&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1871402122001539&tid=spdf-0ce1060b-40db-4efd-a18b-9e2c778e78fc&sid=c562ac0f1b9ec4483e7a73c6f248d9becd08gxrqa&type=client&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t&ua=05075b04570402065504&rr=8d0fad6b1c7dac0f&cc=ca Document source: Diabetes & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260263/pdf/main.pdf Document source: Contemporary Clinical Trials Communications Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260566/pdf/10.1177_20406223221108064.pdf Document source: Therapeutic Advances in Chronic Disease Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515581/pdf/fphar-13-935823.pdf Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769143/pdf/dmso-15-3961.pdf Document source: Diabetes, Metabolic Syndrome and Obesity Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791739/pdf/13098_2022_Article_970.pdf Document source: Diabetology & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758543/pdf/JAFES-37-2-65.pdf Document source: Journal of the ASEAN Federation of Endocrine Societies Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs) Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840940/pdf/cureus-0014-00000032610.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline Document link: https://www.bmj.com/content/373/bmj.n1091 Document source: British Medical Journal Document type: Clinical Practice Guidelines Document year: 2021

Document title: Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials Document link: https://www.jstage.jst.go.jp/article/endocrj/68/6/68_EJ21-0129/_pdf/-char/en Document source: Endocrine Journal Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis Document link: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(21)00264-3/abstract Document source: Diabetes Research and Clinical Practice Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747170/pdf/10.1177_0271678X20952011.pdf Document source: Journal of Cerebral Blood Flow and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549924/?report=printable Document source: The Journal of Clinical Endocrinology and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association Document link: https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000000766 Document source: American Heart Association Document type: Clinical Practice Guidelines Document year: 2020

Document title: Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539133/pdf/IJE2020-1626484.pdf Document source: International Journal of Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848399/pdf/13300_2019_Article_706.pdf Document source: Diabetes Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2019

Trulicity

Drug name: Trulicity | Dosage form: Injection (subcutaneous: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL) | Approval year: 2014 | Company: Eli Lilly and Company, Indianapolis, IN | Class: Glucagon-like peptide 1 (GLP-1) receptor agonists | System: Multiple

Indications

Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Document title: The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.14125 Document source: European Journal of Clinical Investigation Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10814593/pdf/diseases-12-00014.pdf Document source: Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10972401/pdf/medicina-60-00357.pdf Document source: Medicina Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis Document link: https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.2483 Document source: Journal of Clinical Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11463578/pdf/cureus-0016-00000069008.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9999488/pdf/12933_2023_Article_1775.pdf Document source: Cardiovascular Diabetology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10328610/pdf/medi-102-e34122.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10277636/pdf/fendo-14-1170881.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Effects of GLP-1 receptor agonists on neurological complications of diabetes Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10404567/pdf/11154_2023_Article_9807.pdf Document source: Reviews in Endocrine & Metabolic Disorders Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Document link: https://academic.oup.com/jcem/article-pdf/108/7/1806/50604554/dgad076.pdf Document source: The Journal of Clinical Endocrinology and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10493284/pdf/fendo-14-1244432.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10500557/pdf/main.pdf Document source: EClinicalMedicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10513082/pdf/fpubh-11-1201818.pdf Document source: Frontiers in Public Health Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9260263/pdf/main.pdf Document source: Contemporary Clinical Trials Communications Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Trulicity (dulaglutide) Prescribing Information. Document link: https://uspl.lilly.com/trulicity/trulicity.html#pi Document source: Eli Lilly and Company, Indianapolis, IN Document type: Product Monograph / Prescribing Information Document year: 2022

Document title: GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice. Document link: https://journals.lww.com/jaanp/fulltext/2022/02000/glp_1_receptor_agonists_and_cardiovascular.32.aspx Document source: Journal of the American Association of Nurse Practitioners Document type: Clinical Practice Guidelines Document year: 2022

Document title: An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9016460/ Document source: The Journal of Clinical Endocrinology and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9097124/pdf/12902_2022_Article_1036.pdf Document source: BMC Endocrine Disorders Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9613929/pdf/fphar-13-998816.pdf Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9622886/pdf/41598_2022_Article_22263.pdf Document source: Scientific Reports Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9791739/pdf/13098_2022_Article_970.pdf Document source: Diabetology & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jcpt.13398 Document source: Journal of Clinical Pharmacy and Therapeutics Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7747170/pdf/10.1177_0271678X20952011.pdf Document source: Journal of Cerebral Blood Flow and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8099977/pdf/13300_2021_Article_1034.pdf Document source: Diabetes Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes? Document link: https://link.springer.com/article/10.1007/s40265-021-01525-x Document source: Drugs Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8442438/pdf/12933_2021_Article_1366.pdf Document source: Cardiovascular Diabetology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials Document link: https://link.springer.com/article/10.1007/s12020-020-02193-9 Document source: Endocrine Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Dulaglutide and insulin: How can the AWARD Studies help guide clinical practice? Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376989/ Document source: Diabetes Therapy Document type: Clinical Practice Guidelines Document year: 2020

Document title: KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Document link: https://www.kidney-international.org/action/showPdf?pii=S0085-2538%2820%2930718-3 Document source: Kidney International Document type: Clinical Practice Guidelines Document year: 2020

Document title: Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7310317/pdf/12933_2020_Article_1070.pdf Document source: Cardiovascular Diabetology Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7547475/pdf/12933_2020_Article_1148.pdf Document source: Cardiovascular Diabetology Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC6848399/pdf/13300_2019_Article_706.pdf Document source: Diabetes Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2019

Victoza

Indications

Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Document title: Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis Document link: https://www.mdpi.com/2079-9721/12/1/14 Document source: Diseases (basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials Document link: https://journals.lww.com/10.1097/MD.0000000000037432 Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists Document link: https://www.mdpi.com/1648-9144/60/3/357 Document source: Medicina (kaunas, Lithuania) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials Document link: https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-024-01371-3 Document source: Diabetology & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease Document link: https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0168/_article Document source: Endocrine Journal Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis Document link: https://onlinelibrary.wiley.com/doi/10.1155/2024/1785321 Document source: International Journal of Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model Document link: https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1201818/full Document source: Frontiers in Public Health Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Victoza (liraglutide) Prescribing Information. Document link: https://www.novo-pi.com/victoza.pdf Document source: Novo Nordisk Inc., Plainsboro, NJ Document type: Product Monograph / Prescribing Information Document year: 2023

Document title: Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs Document link: https://journals.lww.com/10.1097/MD.0000000000032892 Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review Document link: https://www.mdpi.com/1422-0067/24/8/7184 Document source: International Journal of Molecular Sciences Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10265718/pdf/etm-26-01-12054.pdf Document source: Experimental and Therapeutic Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis Document link: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1170881/full Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review Document link: https://www.dovepress.com/effect-of-liraglutide-on-fat-mass-percentage-among-overweight-and-obes-peer-reviewed-fulltext-article-DMSO Document source: Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials Document link: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-03129-6 Document source: Bmc Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review Document link: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1244432/full Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies Document link: https://www.tandfonline.com/doi/full/10.1080/09546634.2021.1882658 Document source: The Journal of Dermatological Treatment Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review Document link: https://onlinelibrary.wiley.com/doi/10.1111/cen.14583 Document source: Clinical Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis Document link: https://onlinelibrary.wiley.com/doi/10.1111/jdi.13775 Document source: Journal of Diabetes Investigation Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials Document link: https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-01036-0 Document source: Bmc Endocrine Disorders Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis Document link: https://linkinghub.elsevier.com/retrieve/pii/S2451-8654(22)00061-8 Document source: Contemporary Clinical Trials Communications Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9993257/pdf/AFHS2203-0267.pdf Document source: African Health Sciences Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis Document link: https://link.springer.com/article/10.1007/s13300-021-01072-4 Document source: Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis Document link: https://journals.viamedica.pl/endokrynologia_polska/article/viewd?doi=10.5603/EP.a2021.0031 Document source: Endokrynologia Polska Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis Document link: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14221 Document source: Diabetes, Obesity & Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis Document link: https://academic.oup.com/jcem/article-lookup/doi/10.1210/clinem/dgaa891 Document source: The Journal of Clinical Endocrinology and Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials Document link: https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(20)30928-6 Document source: European Journal of Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis Document link: https://linkinghub.elsevier.com/retrieve/pii/S0168-8227(21)00264-3 Document source: Diabetes Research and Clinical Practice Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Anti-diabetic drugs and weight loss in patients with type 2 diabetes Document link: https://linkinghub.elsevier.com/retrieve/pii/S1043-6618(21)00366-2 Document source: Pharmacological Research Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis Document link: https://link.springer.com/article/10.1007/s13300-021-01034-w Document source: Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Document link: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.618208/full Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review Document link: https://linkinghub.elsevier.com/retrieve/pii/S1871-4021(21)00117-X Document source: Diabetes & Metabolic Syndrome Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials Document link: https://link.springer.com/article/10.1007/s00059-018-4748-5 Document source: Herz Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis Document link: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.00553/full Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies Document link: https://drc.bmj.com/content/8/1/e001020.long Document source: Bmj Open Diabetes Research & Care Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies Document link: https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(20)30054-8 Document source: Metabolism: Clinical and Experimental Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes Document link: https://www.jstage.jst.go.jp/article/endocrj/67/4/67_EJ19-0530/_article Document source: Endocrine Journal Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis Document link: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.13899 Document source: Diabetes, Obesity & Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. Document link: https://link.springer.com/content/pdf/10.1186/s13098-020-00551-1.pdf Document source: Diabetology & Metabolic Syndrome Document type: Clinical Practice Guidelines Document year: 2020

Document title: Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials Document link: https://www.tandfonline.com/doi/full/10.1080/10641963.2019.1676771 Document source: Clinical and Experimental Hypertension (new York, N.y. : 1993) Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Document link: https://www.canadianjournalofdiabetes.com/article/S1499-2671(20)30228-8/abstract Document source: Canadian Journal of Diabetes Document type: Clinical Practice Guidelines Document year: 2020

Document title: Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis Document link: https://www.eurekaselect.com/article/98812 Document source: Current Diabetes Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis Document link: https://link.springer.com/article/10.1007/s13300-019-00706-y Document source: Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Document type: Systematic Reviews / Meta-Analyses Document year: 2019

Zepbound

Indications

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity)
Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease).

Document title: Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials Document link: https://link.springer.com/article/10.1007/s11096-024-01779-x Document source: International Journal of Clinical Pharmacy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Zepbound (tirzepatide) Prescribing Information. Document link: https://pi.lilly.com/us/zepbound-uspi.pdf Document source: Lilly USA, LLC., Indianapolis, IN Document type: Product Monograph / Prescribing Information Document year: 2024

Document title: Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864442/pdf/fpubh-12-1277113.pdf Document source: Frontiers in Public Health Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10873148/pdf/dmso-17-701.pdf Document source: Diabetes, Metabolic Syndrome and Obesity Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial Document link: https://link.springer.com/article/10.1007/s12020-024-03896-z Document source: Endocrine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446893/pdf/fendo-14-1230206.pdf Document source: Frontiers in Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Weight loss efficiency and safety of tirzepatide: A Systematic review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159347/pdf/pone.0285197.pdf Document source: PloS One Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable? Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084319/pdf/fendo-14-1121387.pdf Document source: Frontiers in Endocrinology, Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Wegovy

Indications

Indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and in adults with overweight in the presence of at least one weight-related comorbid condition

Document title: Emerging Pharmacotherapies for Obesity: A Systematic Review Document link: https://pharmrev.aspetjournals.org/content/early/2024/09/20/pharmrev.123.001045.long Document source: Pharmacological Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Wegovy (semaglutide) Prescribing Information. Document link: https://www.novo-pi.com/wegovy.pdf Document source: Novo Nordisk Inc., Plainsboro, NJ Document type: Product Monograph / Prescribing Information Document year: 2024

Document title: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis Document link: https://linkinghub.elsevier.com/retrieve/pii/S1530-891X(23)00758-9 Document source: Endocrine Practice : Official Journal Of The American College Of Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis Document link: https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(24)00031-3 Document source: Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses Document link: https://onlinelibrary.wiley.com/doi/10.1111/ijpo.13113 Document source: Pediatric Obesity Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10923257/pdf/cr-15-001.pdf Document source: Cardiology Research Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment Document link: https://link.springer.com/article/10.1007/s40618-024-02361-y Document source: Journal Of Endocrinological Investigation Document type: Clinical Practice Guidelines Document year: 2024

Document title: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Document link: https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(24)00319-9 Document source: The American Journal Of Cardiology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials Document link: https://onlinelibrary.wiley.com/doi/10.1111/obr.13792 Document source: Obesity Reviews : An Official Journal Of The International Association For The Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review Document link: https://onlinelibrary.wiley.com/doi/10.1111/cob.12690 Document source: Clinical Obesity Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison Document link: https://link.springer.com/article/10.1007/s12325-024-02941-7 Document source: Advances In Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis Document link: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1379189/full Document source: Frontiers In Cardiovascular Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis Document link: https://www.mdpi.com/1424-8247/17/7/828 Document source: Pharmaceuticals (Basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline Document link: https://onlinelibrary.wiley.com/doi/10.1111/ijpo.13169 Document source: Pediatric Obesity Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11376316/pdf/cureus-0016-00000066280.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials Document link: https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(24)00266-X Document source: Metabolism: Clinical And Experimental Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis Document link: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1453297/full Document source: Frontiers In Cardiovascular Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies Document link: https://www.mdpi.com/2079-9721/12/9/204 Document source: Diseases (Basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis Document link: https://journals.sagepub.com/doi/10.1177/17562864241281903?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Document source: Therapeutic Advances In Neurological Disorders Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain Document link: https://www.cambridge.org/core/journals/cns-spectrums/article/systematic-review-on-the-efficacy-of-glp1-receptor-agonists-in-mitigating-psychotropic-drugrelated-weight-gain/48801F4A9CE25AE46D43F26B8847E8EB Document source: Cns Spectrums Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials Document link: https://onlinelibrary.wiley.com/doi/10.1111/obr.13543 Document source: Obesity Reviews : An Official Journal Of The International Association For The Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials Document link: https://onlinelibrary.wiley.com/doi/10.1111/obr.13553 Document source: Obesity Reviews : An Official Journal Of The International Association For The Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis Document link: https://bmjopen.bmj.com/content/13/3/e061807.long Document source: Bmj Open Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials Document link: https://www.dovepress.com/the-efficacy-of-glp-1-analogues-on-appetite-parameters-gastric-emptyin-peer-reviewed-fulltext-article-DMSO Document source: Diabetes, Metabolic Syndrome And Obesity : Targets And Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials Document link: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15138 Document source: Diabetes, Obesity & Metabolism Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis Document link: https://linkinghub.elsevier.com/retrieve/pii/S0149-2918(23)00194-7 Document source: Clinical Therapeutics Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials Document link: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1132004/full Document source: Frontiers In Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis Document link: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1149328/full Document source: Frontiers In Endocrinology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs) Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9840940/pdf/cureus-0014-00000032610.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9758543/pdf/JAFES-37-2-65.pdf Document source: Journal Of The Asean Federation Of Endocrine Societies Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis Document link: https://www.dovepress.com/semaglutide-24-mg-for-the-management-of-overweight-and-obesity-systema-peer-reviewed-fulltext-article-DMSO Document source: Diabetes, Metabolic Syndrome And Obesity : Targets And Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review Document link: https://www.dovepress.com/efficacy-and-safety-of-liraglutide-and-semaglutide-on-weight-loss-in-p-peer-reviewed-fulltext-article-CLEP Document source: Clinical Epidemiology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials Document link: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.935823/full Document source: Frontiers In Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review Document link: https://journals.sagepub.com/doi/abs/10.1177/20406223221108064?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Document source: Therapeutic Advances In Chronic Disease Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis Document link: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1844-1176 Document source: Hormone And Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis Document link: https://linkinghub.elsevier.com/retrieve/pii/S2589-5370(21)00494-6 Document source: Eclinicalmedicine Document type: Systematic Reviews / Meta-Analyses Document year: 2021